# GSK plc (GSK)

Source: https://www.quantisnow.com/company/GSK
Generated: 2026-11-09T07:51:29.682Z

- Ticker: GSK
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2022
- SEC CIK: 0001131399
- Website: gsk.com

## About

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

## Latest GSK news and filings

- 2026-11-06 15:08 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6778341)
- 2026-11-05 21:06 UTC [SEC Form 13F-HR filed by GSK plc](https://www.quantisnow.com/insight/sec-form-13f-hr-filed-by-gsk-plc-6776265)
- 2026-11-03 22:45 UTC [FDA Approval for BENLYSTA issued to GLAXOSMITHKLINE LLC](https://www.quantisnow.com/insight/fda-approval-for-benlysta-issued-to-glaxosmithkline-llc-6770624)
- 2026-11-03 21:03 UTC [Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine](https://www.quantisnow.com/insight/alamar-biosciences-partners-with-gsk-on-large-scale-proteomic-study-to-6769389)
- 2026-11-02 15:41 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6766613)
- 2026-11-02 13:00 UTC [Alfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026](https://www.quantisnow.com/insight/alfasigma-announces-new-linerixibat-data-across-pbc-and-liver-disease-6766212)
- 2026-10-29 10:31 UTC [Analyst Downgrade] [GSK plc downgraded by Jefferies with a new price target](https://www.quantisnow.com/insight/gsk-plc-downgraded-by-jefferies-with-a-new-price-target-6762189)
- 2026-10-28 14:45 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6760868)
- 2026-10-26 16:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6757368)
- 2026-10-26 16:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6757365)
- 2026-10-26 10:51 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6756862)
- 2026-10-26 10:32 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6756842)
- 2026-10-21 10:14 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6752726)
- 2026-10-20 23:58 UTC [Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)](https://www.quantisnow.com/insight/hibsago-bepirovirsen-approved-in-the-us-for-the-treatment-of-6752564)
- 2026-10-19 22:18 UTC [Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer](https://www.quantisnow.com/insight/jemperli-dostarlimab-gxly-approved-in-us-as-first-and-only-immunotherapy-6751072)
- 2026-10-19 17:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6750385)
- 2026-10-19 11:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6749862)
- 2026-10-15 14:47 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6747718)
- 2026-10-14 15:42 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6746307)
- 2026-10-13 15:35 UTC [SEC Form S-8] [SEC Form S-8 filed by GSK plc](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-gsk-plc-6744758)
- 2026-10-13 15:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6744743)
- 2026-10-13 10:27 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6743982)
- 2026-10-09 12:28 UTC [Analyst Coverage Initiated] [Wolfe Research initiated coverage on GSK plc with a new price target](https://www.quantisnow.com/insight/wolfe-research-initiated-coverage-on-gsk-plc-with-a-new-6742431)
- 2026-10-08 15:42 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6741494)
- 2026-10-08 11:38 UTC [Viola Davis partners with GSK to educate adults 50 and older about their shingles risk](https://www.quantisnow.com/insight/viola-davis-partners-with-gsk-to-educate-adults-50-and-6741065)
- 2026-10-06 14:43 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6738586)
- 2026-10-01 14:57 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6731932)
- 2026-09-24 14:44 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6725157)
- 2026-09-22 15:05 UTC [SEC Form CERT filed by GSK plc](https://www.quantisnow.com/insight/sec-form-cert-filed-by-gsk-plc-6722747)
- 2026-09-22 14:52 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6722731)
- 2026-09-15 12:48 UTC [Analyst Upgrade] [GSK plc upgraded by Berenberg](https://www.quantisnow.com/insight/gsk-plc-upgraded-by-berenberg-6715564)
- 2026-09-15 10:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6715238)
- 2026-09-14 11:24 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6713693)
- 2026-09-14 11:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6713677)
- 2026-09-11 14:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6712679)
- 2026-09-10 14:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6711244)
- 2026-09-10 10:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6710697)
- 2026-09-09 14:45 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6709746)
- 2026-09-09 14:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by GSK plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gsk-plc-6709739)
- 2026-09-09 13:33 UTC [Analyst Coverage Initiated] [RBC Capital Mkts initiated coverage on GSK plc](https://www.quantisnow.com/insight/rbc-capital-mkts-initiated-coverage-on-gsk-plc-6709671)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GSK
- Earnings history: https://www.quantisnow.com/earnings/GSK
- Dividend history: https://www.quantisnow.com/dividends/GSK
- Insider transactions: https://www.quantisnow.com/insiders/GSK
- Options chain: https://www.quantisnow.com/options/GSK
- SEC 8-K filings only: https://www.quantisnow.com/company/GSK/8-k
- RSS and alerts for GSK: https://www.quantisnow.com/docs/rss-feeds.md